Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis

NCT07386717 | Completed

• 1 other identifier: UVIPWP_V1
• Study Type: observational
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life. Although targeted therapies such as Janus kinase inhibitors and interleukin-17 inhibitors have demonstrated efficacy in randomized controlled trials, real-world comparative evidence between these treatment strategies remains limited. This observational cohort study aims to compare the real-world effectiveness and safety of upadacitinib and interleukin-17 inhibitors in patients with PsA over a 24-week follow-up period. By evaluating clinical outcomes under routine clinical practice conditions, this study seeks to provide evidence to support individualized treatment selection in PsA management.

Conditions

Psoriatic Arthritis; Upadacitinib; Interleukin-17 Inhibitors

Keywords

Interleukin-17 Inhibitors; Upadacitinib; Psoriatic Arthritis

Outcome Measures

Primary Outcomes (1)

• Clinical effectiveness of treatment

  Changes in joint and skin disease activity assessed using validated clinical measures during the 24-week follow-up period.

  Baseline to Week 24

Study Arms (2)

Cohort 1: Upadacitinib-Treated PsA Patients

Adult patients with psoriatic arthritis receiving upadacitinib as part of routine clinical care and followed for 24 weeks.

Cohort 2: IL-17 Inhibitor-Treated PsA Patients

Adult patients with psoriatic arthritis receiving interleukin-17 inhibitors (e.g., secukinumab or ixekizumab) as part of routine clinical care and followed for 24 weeks.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Diagnosis of psoriatic arthritis according to established classification criteria

You may qualify if:

• Age ≥ 18 years
• Diagnosis of psoriatic arthritis according to established classification criteria
• Treatment with upadacitinib or an interleukin-17 inhibitor at baseline
• Availability of baseline and follow-up clinical data over 24 weeks

You may not qualify if:

• Diagnosis of other inflammatory arthritides
• History of malignancy or severe uncontrolled infection
• Incomplete clinical data preventing outcome assessment

Sponsors & Collaborators

• Peking University First Hospital: lead

Study Sites (1)

Peking University First Hospital

Beijing, China

Location

MeSH Terms

Conditions

Arthritis, Psoriatic

Condition Hierarchy (Ancestors)

Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 27, 2026
• First Posted: February 4, 2026
• Study Start: January 1, 2024
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: February 4, 2026

Record last verified: 2026-01

Locations

CN (1)